Changes in Body Weight and Psychotropic Drugs: A Systematic Synthesis of the Literature

Abstract

IntroductionPsychotropic medication use is associated with weight gain. While there are studies and reviews comparing weight gain for psychotropics within some classes, clinicians frequently use drugs from different classes to treat psychiatric disorders.ObjectiveTo undertake a systematic review of all classes of psychotropics to provide an all encompassing evidence-based tool that would allow clinicians to determine the risks of weight gain in making both intra-class and interclass choices of psychotropics.Methodology and ResultsWe developed a novel hierarchical search strategy that made use of systematic reviews that were already available. When such evidence was not available we went on to evaluate randomly controlled trials, followed by cohort and other clinical trials, narrative reviews, and, where necessary, clinical opinion and anecdotal evidence. The data from the publication with the highest level of evidence based on our hierarchical classification was presented. Recommendations from an expert panel supplemented the evidence used to rank these drugs within their respective classes. Approximately 9500 articles were identified in our literature search of which 666 citations were retrieved. We were able to rank most of the psychotropics based on the available evidence and recommendations from subject matter experts. There were few discrepancies between published evidence and the expert panel in ranking these drugs.ConclusionPotential for weight gain is an important consideration in choice of any psychotropic. This tool will help clinicians select psychotropics on a case-by-case basis in order to minimize the impact of weight gain when making both intra-class and interclass choices.

Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment

“…However, the effect of each antidepressant may be influenced by several individual characteristics (e.g., sex, BMI, previous medication history, genetic polymorphisms) and generally becomes more evident over the long term (Dent et al, 2012). Weight gain is also a common problem associated with many atypical antipsychotics such as clozapine and olanzapine, and also increases the risk of metabolic disorders such as diabetes mellitus and dyslipidaemia (Dent et al, 2012, Gautam and Meena, 2011, Newcomer, 2005, Rummel-Kluge et al, 2010.…”

“…Weight gain is also a common problem associated with many atypical antipsychotics such as clozapine and olanzapine, and also increases the risk of metabolic disorders such as diabetes mellitus and dyslipidaemia (Dent et al, 2012, Gautam and Meena, 2011, Newcomer, 2005, Rummel-Kluge et al, 2010.…”

A 680 kb duplication at the FTO locus in a kindred with obesity and a distinct body fat distribution

“…Exclusion criteria included medical or psychiatric conditions and medications affecting body weight. 15 Body weight was assessed using a Tanita electronic scale to the nearest 0.3 kg. Height was measured to the nearest 0.5 cm.…”

Induction of NAFLD with Increased Risk of Obesity and Chronic Diseases in Developed Countries

“…fluoxetine, sertraline, fluvoxamine, and bupropion) used for weight loss in clinical trials and the treatment of mood disorders (antidepressants and antiepileptics). Drug induced weight gain [165] also includes a systematic review of intra-class and inter-class psychotropic drugs [166]- [168] that allow poor recommendations of various psychotropic drugs involved in weight gain and the induction of obesity.…”